GU Cancers 2024 | ARCADIA: peripheral biomarker analysis in urothelial carcinoma

Patrizia Giannatempo, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses findings from the interim analysis of the Phase II ARCADIA trial (NCT03824691), which assessed cabozantinib, a tyrosine kinase inhibitor, and durvalumab in patients with recurrent or progressed urothelial carcinoma. A subset analysis of peripheral blood biomarkers aimed to identify associations with clinical response and preliminary results indicate higher baseline counts of certain immune subsets, including granulocytes, monocytes, and myeloid-derived suppressor cells (MDSCs), may negatively impact treatment response. Additionally, baseline neutrophil and eosinophil counts show opposite effects on progression-free survival. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.